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Assessing Health Effects 
of Chemical Mixtures
There is no question that many chemicals
cause human disease. Arsenic and skin can-
cer, asbestos and lung cancer, lead and decre-
ments of IQ, and dioxin and chloracne are
examples of well-documented effects.
However, most people are not exposed to
only a single chemical compound. Although
the health effects of single contaminants may
be apparent under circumstances of high
exposure, the great majority of people are
exposed to chemical mixtures of organics
and inorganics at lower concentrations. And
though each of these contaminants individu-
ally may increase risk of certain diseases, the
question of how contaminants interact
remains a relatively unexplored subject but
one recently recognized for its increasing
importance (1–4).
The study of chemical mixtures is lim-
ited for a number of reasons. It is much eas-
ier to study a single compound in an animal
study and to obtain traditional dose–
response information. An almost infinite
number of combinations of contaminants is
possible, and often we do not know which is
most important, or which dose ranges
should be investigated, or which biologic
end points should be studied. Although rela-
tively few studies have investigated the inter-
actions of even two chemicals, in real life we
are all exposed to multiple substances, and
the biologic effects of 20 different chemicals
may be very different from those of just two.
Furthermore, even the statistics relating to
how one deals with complex mixtures is a
newly developing science (2).
The number of chemicals to which
humans are exposed has increased dramati-
cally in the past 100 years. Mankind has
always been exposed to various metals,
which as natural elements are present
throughout the environment, in drinking
water, and in food. Many natural chemicals
are in the foods that we eat, and many of
these act at a variety of sites in different
organs and cells. Polycyclic aromatic hydro-
carbons (PAHs), formed by combustion,
have been a source of exposure since humans
learned to produce fire. With the develop-
ment of the use of fossil fuels for many pur-
poses, humans have become exposed to a
greater range of hydrocarbons and their by-
products. But the number of chemicals pro-
duced by the chemical and pharmaceutical
industries in the twentieth century has vastly
increased human exposure. We produce
almost all food crops through use of pesti-
cides, herbicides, and fungicides. We pro-
duce meat products through extensive use of
growth stimulants and antibiotics. The rapid
development in use of plastics has resulted in
exposure to various chemicals that may leach
into food. The number of medicines has
increased enormously, most of which are
clearly of benefit to human health but still
have the possibility of interactions with
other environmental agents. Pimentel et al.
(5) report that some 80,000 chemicals are in
use today, that nearly 10% are recognized as
carcinogens, and that use of chemicals has
increased 3-fold from 1941 to 1995. Many
of these compounds have not been ade-
quately tested for human toxicity. For exam-
ple, the National Toxicology Program has
published only 605 reports of long- or short-
term study of chemicals, a very small propor-
tion of those in use today.
Interactions of Chemicals 
in Biologic Systems
Chemicals can interact in a number of ways.
If we consider two chemicals, they may act at
a common site such as a receptor or an
enzyme. In this case their actions may be
additive if both activate the target, or occlu-
sive if one activates and the other binds with-
out activating or binds with a slow
dissociation constant. However, many effects
are more complex than simply binding to a
receptor or enzyme and act through some
combination of altering gene expression,
changing levels of intracellular concentrations
of ions, altering cellular metabolism or pro-
duction of cellular regulators. Under these
circumstances the effect of mixtures is more
difﬁcult to predict. In reality, few chemicals
have only a single cellular target. Most act at
multiple sites on different cell types or in
some cases even at multiple targets within the
same cell type. There may be quite different
actions on the kidney, the liver, and the
brain, each with a different disease-related
outcome. The actions at each of these sites
depend on the presence of genes, receptors,
and cellular regulators in the specific cell
types. When targets that regulate other
organs and cells are affected (e.g., the thyroid
or the beta cells of the pancreas), the impact
of the chemical agent is much greater.
Much of the contemporary concern
about chemical mixtures stems from the pos-
sibility of compounds having synergistic, or
more than additive, effects. We have a few
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We have strong evidence that inhalation of
radon progeny and current smoking have
synergistic effects on the incidence of lung
cancer (6). We even have evidence that quit-
ting smoking decreases lung cancer risk from
radon more than reduction of radon expo-
sure (7). We also have strong evidence that
smoking and exposure to asbestos exert syn-
ergistic effects on incidence of lung cancer
[see Erren et al. (8)]. Obviously smoking,
considered alone, represents an exposure to a
very complex chemical mixture, but this
does not alter the clear evidence that the
addition of a second environmental factor,
either radon or asbestos, results in more than
an additive risk of injury. However, we have
little additional documentation of how mix-
tures in humans interact, and little investiga-
tion of this question even in animals.
Routes of Exposure and Exposure
Assessment
Exposure to chemical mixtures may result
from ingestion, inhalation, or dermal absorp-
tion. Often the route of exposure deﬁnes the
site of disease. For example, smoking causes
lung cancer, and mutagenic substances
applied to the skin cause skin cancer. Some
contaminants may induce differential effects
depending on the route of exposure—for
example, asbestos inhaled versus asbestos
ingested. This is understandable because site
of application reﬂects local mutagenic effects
or generation of reactive substances, such as
reactive oxygen species (ROS; discussed
below). The body rapidly absorbs and dis-
tributes other toxicants regardless of the route
of exposure, and the health outcomes are not
specific to route of exposure. For the more
persistent contaminants, the route of expo-
sure is less signiﬁcant because they are present
long enough to equilibrate in the body.
Because different kinds of contaminants may
have different reservoirs in the body (e.g.,
metals to bone and teeth, organics to adipose
tissue), toxic actions in the reservoirs may
also be predictive of disease there. However,
each of these reservoirs is usually in equilib-
rium with levels in blood and tissues.
A full discussion of exposure assessment
is beyond the scope of this review because it
is one of the most difﬁcult problems facing
environmental health scientists. Some sub-
stances are persistent in the body, and direct
measurement of concentration in body ﬂuids
or tissues provides information that allows
one to estimate exposure. However, even
these cases almost always involve some
metabolism and/or excretion, so determining
the degree of exposure in the past is difﬁcult.
On the other hand, many other toxic
substances are not persistent and may exert
harmful effects that last long after the agent is
no longer present in the body. Assessing
exposure to these substances is more difﬁcult.
Some do leave biomarkers of exposure, such
as DNA or protein adducts, and study of
such adducts is an active area of investigation.
Many carcinogenic substances induce gene
mutations as the primary event, activating
oncogenes or inactivating tumor suppressor
genes, and such mutations can be monitored
as biomarkers of exposure (9). Therefore, all
too often the environmental health scientist
is left with only interview reports of exposure,
occupational history, or other less rigorous
evidence from which to draw conclusions
about relationship to disease.
One of the few standard methods for
dealing with exposure assessment of mix-
tures has been the use of toxic equivalent
factors (TEFs) for dioxinlike substances
(10). Because dioxins, furans, some poly-
chlorinated biphenyls (PCBs), and some
PAHs all act at the aromatic hydrocarbon
receptor (AhR) to induce a proﬁle of effects
(many of them adverse), assays that deter-
mine the degree of AhR activation are often
used to evaluate mixture toxicity (11). This
approach assumes that all substances acting
at the AhR produce the same profile of
effects and that the actions are additive.
Although such an approach has clear value
in determining the toxicity of a complex
mixture, it also has some major limitations.
Different species differ in potency, with val-
ues usually derived from short-term, in vitro
studies that ignore the toxicokinetics (1).
Wölﬂe (12) has shown that polychlorinated
dibenzodioxins (PCDDs) plus PCB 126
have additive effects, as we might predict,
whereas PCB 153, a di-ortho congener that
does not strongly activate the AhR, antago-
nized the PCDD action. AhR activation
does not mediate many effects of PCBs.
Because of the widespread acceptance of the
use of TEFs for dioxin toxicity, many peo-
ple ignore the non–dioxin-like effects of
such agents as the noncoplanar PCBs. These
other PCBs may not be as carcinogenic as
the coplanar ones, but the health outcomes
from these other congeners (neurobehav-
ioral abnormalities, endocrine and meta-
bolic disruption) may in fact be of greater
overall importance than cancer. Other
assays have proven valuable for analysis of
other parameters of mixtures, such as estro-
genic activity (13,14), but none of these has
utility for mixtures of organics and metals
or other combinations for which the initial
action is not at a common site.
Environmental Contributions
to Human Disease
A critical ﬁrst question in evaluating the role
of chemical mixtures in human disease is to
discuss the degree to which environmental
agents contribute to disease in general. Even
on this issue, there is no widespread consen-
sus. Murray and Lopez (15) have estimated
that environmental factors (chemicals, radia-
tion, and tobacco smoke together) are
responsible for roughly 80% of all cancers.
Smith et al. (16) have estimated that
25–33% of the total global burden of disease
can be attributed to environmental factors
and that children are particularly vulnerable
to environmental factors. This estimate
includes diseases secondary to infectious
agents transmitted through the environ-
ment. In recent years, evidence has emerged
for a contribution of environmental agents
to a number of diseases that have not previ-
ously been considered to have environmental
causes. This is especially true for the general
categories of diseases considered under the
rubric of endocrine disruption, as well as a
number of chronic diseases such as cardio-
vascular disease (see below), diabetes
(17–19), and even bone, joint, and interver-
tebral disk disease (20). In many of these sit-
uations we have some evidence for a variety
of chemicals having a relationship to the dis-
ease, but we currently have little or no evi-
dence of the nature and effects of
interactions among chemicals related to the
disease state.
We can divide the diseases that we sus-
pect have a relationship to environmental
agents into two broad categories: those
agents that interfere with normal develop-
ment and distort physiologic function and
those that cause direct cellular damage.
Although it is not possible to discuss in this
review all the human diseases that environ-
mental chemicals inﬂuence, and although we
have little or no rigorous information on the
actions of chemical mixtures for most of
these diseases, we use several diseases in each
category as examples of the present state of
our knowledge and the research questions
that need to be addressed.
Human Diseases Based on
Current Understanding of
Physiologic Mechanisms
Many environmental agents act to alter the
biochemistry and physiology of the organ-
ism, but they do so without necessarily
shortening life or even causing overt disease.
If these actions occur during development,
they can result in permanent, life-long
differences in physical size, intelligence,
behavior, reproductive ability, and suscepti-
bility to other diseases. Even later in life such
exposures may alter mental and sexual func-
tions. Many use the term “endocrine disrup-
tion” to encompass these different effects,
but this term is inadequate to include the
full range of alterations that may result in
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secondary to changes in the endocrine sys-
tems. Furthermore, some of the changes in
physiologic function may not, when consid-
ered alone, result in cellular damage, but
they may increase risk of disease, as
described below for cardiovascular disease in
relation to factors that increase serum lipids.
We describe two categories of disease below
to illustrate these points.
Neurobehavioral Abnormalities
In 1979 Needleman et al. (21)ﬁ rst reported
clear evidence that exposure of young chil-
dren to lead resulted in both a decrement in
IQ and the development of a series of dis-
ruptive behaviors characterized by a short-
ened attention span. They followed these
children for a number of years, and later
Needleman et al. (22) concluded that the
effects of lead on neurobehavior function
were essentially irreversible, in that the
decrements did not diminish with time.
Consistent with this conclusion is the obser-
vation of Rogan et al. (23) that lead chela-
tion reduces blood lead levels in children
over 2–3 years old but will not reverse the
neurocognitive deficits. Although the IQ
deficits were only in the range of 5–7 IQ
points and therefore probably do not result
in enormous differences in individual perfor-
mance, from a societal perspective, a system-
atic “dumbing down” of the population has
enormous consequences.
More recently it has become clear that
several organic pollutants have similar
effects. The Yucheng cohort in Taiwan had
prenatal exposures to a mixture of PCBs and
furans, and these children showed a similar
5- to 7-point IQ deﬁcit that did not disap-
pear with time (24). These children also
showed disordered and mildly antisocial
behavior (25), which is very similar to that
described by Needleman et al. (21) in their
initial lead study. Neurobehavioral decre-
ments have been conﬁrmed in several popu-
lations in the United States exposed to PCBs
through consumption of contaminated fish
(26,27) or general diet (28), although in all
these studies the PCBs were not the only
contaminant to which subjects had been
exposed. Fish, in particular, often contain
significant amounts of methyl mercury,
which also has significant neurobehavioral
effects in humans at very high exposure lev-
els (29). Significant controversy remains as
to whether methyl mercury, at the concen-
trations accumulated in populations that
consume a large amount of ﬁsh and marine
mammals, causes neurobehavioral damage.
Davidson et al. (30) have studied the popu-
lation of the Seychelles, where levels of
methyl mercury are high, and found—if
anything—superior performance in those
children with higher methyl mercury levels,
which they attribute to the beneﬁcial effects
of fish consumption. On the other hand,
Grandjean et al. (31) studied the population
of the Faroe Islands, who also eat a lot of
ﬁsh, and reported signiﬁcant decrements of
IQ and abnormalities of behavior in children
that increase with exposure levels. We have
some evidence that adults who eat a signiﬁ-
cant amount of contaminated fish suffer
from some cognitive deficits, attributed in
different regions to methyl mercury by
Mergler et al. (32) and to PCBs by Schantz
et al. (33). One major question is whether it
is the methyl mercury or the PCBs, both of
which are present in most situations, that
cause these effects, or whether perhaps it is
the combination of the two. A recent report
by Bemis and Seegal (34) provides some evi-
dence for a synergistic interaction between
methyl mercury and PCBs in reducing the
content of the neurotransmitter dopamine
from brain.
Pesticide exposure has also been reported
to have adverse effects on neurobehavioral
functioning. Guillette et al. (35) studied
children of two ethnic minority communi-
ties in Mexico: in one community the people
lived and worked on a plain with heavy agri-
culture using a variety of pesticides; the
other community was in the foothills, which
had little or no agriculture. The children
exposed to pesticides had significantly less
ability to draw a human form, and they
demonstrated a variety of motor deﬁcits for
simple tasks.
Animal studies have shown decrements
in ability to learn as a result of exposure to
lead (36), PCBs (37), dioxins (38), and
organophosphate pesticides (39). However,
with the notable exception of the study of
Bemis and Seegal (34) (which was not a
study of learning), there has been no sys-
tematic study of mixtures of lead, methyl
mercury, PCBs, furans, dioxins, or various
pesticides on learning and memory, either
in humans or in animals. We do not well
understand the mechanisms by which these
substances cause neurobehavioral effects.
Although disruption of some endocrine sys-
tems, especially thyroid hormone, can result
in neurobehavioral decrements, and
although several xenobiotics alter thyroid
function (40), it is clear that lead and PCBs,
at least, have a direct effect on nervous sys-
tem function that is not mediated by
alteration of thyroid hormone. Lead (41)
and PCBs (42) both block the process of
long-term potentiation, a form of synaptic
plasticity that has often been used as a
model system for study of cognitive poten-
tial (43). These actions occur both with
chronic perinatal exposure of the developing
animal and with acute in vitro application of
the toxicant. Experimental hypothyroidism
also reduces long-term potentiation (44).
We urgently need to study the effects of
mixtures of metals, PCBs, and pesticides on
neurobehavioral function, both their direct
actions on the brain and their interactions
with altered endocrine systems, especially
thyroid function.
Sex Steroid Hormonal Disruption
The developing organism is exquisitely sensi-
tive to alterations in hormone function. In
the early embryonic state, the gonads of
human males and females are morphologi-
cally identical. Sexual differentiation begins
under hormonal influence during the fifth
and sixth weeks of fetal development, and
thus alteration of hormone function during
this highly sensitive period can have pro-
found, often debilitating, consequences. The
balance of estrogens and androgens is critical
for normal development, growth, and func-
tioning of the reproductive system. Although
it is especially important during develop-
ment, this balance is important throughout
life for preservation of normal feminine or
masculine traits.
A number of environmental chemicals
have actions that mimic or alter the normal
sex steroid hormones. The fetus is especially
vulnerable because this is the period of time
when organs develop. If the normal balance
between estrogens and androgens is dis-
rupted, the result may be feminization of
males, masculinization of females, birth
defects of the reproductive organs, reduced
fertility, and alteration of the expression of
normal feminine or masculine personality
traits, probably including sexual preference.
These effects during development are of par-
ticular significance because they are often
irreversible, and the child must live with the
altered reproductive and sexual function for
the rest of his or her life. For adults, there is
concern about the influence of endocrine-
disruptive chemicals on the incidence of can-
cer of the reproductive organs and on diseases
such as endometriosis, fibroids, prostate
hyperplasia, and reduced sperm counts.
Much of the evidence for developmental
alterations with estrogenic substances comes
from the use of diethylstilbestrol by women
some years ago as an agent thought to prevent
pregnancy loss. This synthetic estrogen caused
a series of developmental abnormalities of
both male and female genital systems, and it
also caused induction of a rare form of vagi-
nal cancer. Newbold (45), comparing effects
reported in humans and in animals, found
immune dysfunction, subfertility, masculin-
ization of females and feminization of males,
abnormalities of both the male and female
reproductive tracts, sperm abnormalities,
and prostatic inflammation upon exposure
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clear whether environmental estrogens have
similar actions, but these abnormalities
define the suspected effects of such com-
pounds. Androgen receptors may also be
targets of action of xenobiotics, as has been
well demonstrated in animal studies
(46,47). DDE [p,p´-bis(4-chlorophenyl)-
1,1, dichloroethane], the major metabolite
of DDT [bis(4-chlorophenyl)-1,1,1-
trichloroethane], is known to be a potent
androgen receptor antagonist (48).
Although many wildlife and animal
studies and a body of information from in
vitro studies have conclusively demonstrated
developmental disruption of estrogenic and
androgenic function, this is not so for
human studies. The problems of proving
that population-based changes in disease pat-
terns and behavior result from exposure to
hormonal disruptors is much more difﬁcult
for human studies than for animal studies,
where one can control exposure to a single
contaminant because humans are always
exposed to chemical mixtures.
One of the few developmental studies in
humans that has convincingly demonstrated
effects of speciﬁc contaminants is that of the
Yucheng cohort in Taiwan, exposed to PCBs
and furans from contaminated cooking oil.
Male children born to mothers with contami-
nation showed decreased penis length but no
effect on testis size or Tanner stages of devel-
opment (49). Blanck et al. (50) showed that
girls exposed in utero to polybrominated
biphenyls reached puberty at a younger age
than unexposed girls. The ﬁndings have some
consistency, indicating an increase in the inci-
dence of endometriosis in women exposed to
PCBs and/or dioxins (51,52), which is consis-
tent with studies in monkeys (53).
Studies evaluating possible associations
between organochlorine compounds and
human male infertility have shown mixed
results. The ratio of male to female births was
reduced for offspring of men heavily exposed
to dioxin in Seveso, Italy (54). In a study of
29 patients and 14 controls, significantly
higher amounts of tetra- and pentachlori-
nated biphenyls, DDE, DDT, and lindane
(γ-hexachlorocyclohexane) were present in
male patients with infertility problems than
in the controls (55). The levels of three PCB
congeners (2,2´,4,4´,5,5´-hexachloro-
biphenyl, 2,2´,3´,4,4´,5-hexachlorobiphenyl,
and 2,3´,4,4´,5-pentachlorobiphenyl) were
inversely correlated with sperm motility
index in samples with a sperm count less
than 20 million cells/mL (56). In contrast, a
clinical laboratory investigation of 38 trans-
former repair workers and 56 control work-
ers with serum PCB levels of 12 ppb and 6
ppb, respectively, did not report differences
in sperm count (57).
Effects on male reproduction are not
limited to organic contaminants. Lead also
functions as an endocrine disruptor, causing
reduced sperm count, reduced semen vol-
ume, and changes in sperm motility and
morphology [for a review, see Apostoli et al.
(58)]. Male lead exposure has been associated
with increased infertility (59). In a classic
study, Lancranjan et al. (60) classified 150
occupationally exposed men into four
groups: those poisoned with lead, those with
moderate levels, those with levels slightly
above baseline, and those with physiologic
levels. Sperm motility decreased and abnor-
mal sperm morphology increased with
increasing lead exposure in a dose–response
relation. A recent study of 149 healthy male
industrial workers (61) reported a signiﬁcant
correlation between blood lead levels and
reproductive parameters, including a decrease
in sperm density, total counts, motility, and
viability. Subpopulations of men with genetic
polymorphisms may be at a higher risk for
developing fertility problems because of envi-
ronmental exposures. Benoff et al. (62) sug-
gest that Ca2+ and K+ channel isoforms
identiﬁed in human testes and spermatozoa
may lead to greater sperm damage in men
exposed to lead and cadmium.
We have considerable evidence that men
in developed countries may have signiﬁcant
decrements in semen quality and quantity,
decreased sperm count, and increases in tes-
ticular cancer, hypospadias, cryptorchidism,
and male breast cancer [for a review, see
Toppari et al. (63)]. A number of investiga-
tors have suggested that these effects are sec-
ondary to increased exposure to estrogenic
xenobiotics (64,65). Whether or not this is
the case awaits further study.
Human Diseases Based 
on Current Understanding 
of Cellular and Molecular
Mechanisms
Neurodegenerative Diseases
The many distinct neurodegenerative diseases
share a number of common features. In each,
speciﬁc populations of neurons die and dis-
appear: upper and lower motor neurons in
amyotrophic lateral sclerosis (ALS), neurons
in the substantia nigra in Parkinson’s disease,
and neurons in frontal cortex and hippocam-
pus in Alzheimer’s disease. For each, a small
minority of cases appear to be genetic, but
the vast majority are random, and for each,
several different environmental agents are
possible contributors to the disease.
There have long been suggestions for a
role of metals, including aluminum, iron,
and lead, in all three of these diseases,
although for none of these diseases are
metals likely to be the sole or even primary
factors. Aluminum in dialysis ﬂuid causes a
clear dementia that appears to be similar to
but distinct from Alzheimer’s disease (66).
We have some epidemiologic evidence for
the incidence of Alzheimer’s disease parallel-
ing that of aluminum in drinking water
(67). These observations have led to consid-
erable speculation about a role for aluminum
in Alzheimer’s disease [see, e.g., Yokel (68)].
The demonstration that aluminum induces a
hyperphosphorylation of tau protein (69), a
major protein in neuroﬁbrillary tangles, has
provided a mechanistic basis for the associa-
tion. Excess aluminum has been implicated
in the high incidence of ALS in the Western
Pacific (70) and has been proposed as an
agent behind the Guam syndrome of
dementia, Parkinson’s disease, and ALS (71).
For many years, evidence has suggested
that lead is a risk factor for some neurode-
generative diseases, especially for ALS.
Campbell et al. (72) and Conradi et al. (73)
reexamined the hypothesis and reported
elevated lead levels in blood and cerebral
fluid from ALS patients. Although others
have not replicated these observations, they
nevertheless acknowledge that lead may be
a contributing factor in the pathogenesis of
disease (74–76). Recent evidence showing
that occupations with exposure to welding,
soldering, and electric plating increase risk
of ALS by 5- to 8-fold is consistent with
this suggestion (77), and the most likely
factor is proposed to be exposure to lead.
Prince (78) has summarized epidemiologic
studies of Alzheimer’s disease incidence,
concluding that this disease is more com-
mon in urban than in rural areas and in
developed than in developing countries. He
concludes that individuals are at greater risk
of Alzheimer’s disease if they show subtle
neuropsychologic deficits and educational
disadvantages and hypothesizes that early
lead exposure could explain these findings.
These observations are compatible with a
number of cellular studies showing that
lead greatly ampliﬁes several other forms of
neuronal damage [for discussion, see
Savolainen et al. (79)]. Savolainen et al.
(79) attribute these actions to lead amplifi-
cation of neurotransmitter-induced ROS
generation, plus an effect of lead to reduce
cellular glutathione levels. Iron has been
suggested to be a factor in neurodegenera-
tive diseases, especially in Parkinson’s dis-
ease, on the basis of the observation that
levels of iron are elevated in the parkinson-
ian substantia nigra and that iron induces
oxidative stress (80,81). Gerlach et al. (81)
also report elevated iron levels in the cau-
date, but not the nigra, in the association
centers, hippocampus, and basal forebrain
in Alzheimer’s disease. Lovell et al. (82)
showed that senile plaques in Alzheimer’s
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Hirsch et al. (83) reported elevated levels of
both iron and aluminum in substantia nigra
from Parkinson’s disease patients.
Although the role of organochlorine
compounds in neurodegenerative diseases
has been less studied, increasing evidence
suggests that organochlorines are involved,
especially in Parkinson’s disease. Schulte
et al. (84) report that incidences of
Parkinson’s disease, Alzheimer’s disease, and
ALS have increased in occupations involving
exposure to pesticides and solvents.
Speciﬁcally for Parkinson’s disease, risk fac-
tors include rural living, well-water con-
sumption, pesticide exposure, and exposure
to solvents (85,86). PCBs are elevated in
brains of Parkinson’s disease patients (87), as
are dieldrin (88) and lindane (89). Exposure
to paraquat has been reported to cause a 3.6-
fold increase in the risk of developing
Parkinson’s disease (90). Bhatt et al. (91)
report ﬁve persons who developed reversible
Parkinson’s disease symptoms following
organophosphate pesticide intoxication.
Ferraz et al. (92) reported Parkinson’s dis-
easelike symptoms in two farm workers
exposed to the fungicide maneb and sug-
gested that the manganese in this fungicide
is the major toxic agent.
Several characteristics of dopaminergic
neurons of the substantia nigra distinguish
them from other neurons, and even from
other dopaminergic neurons. These consid-
erations have led to a general belief that
excessive generation of ROS is likely to be a
major factor in development of Parkinson’s
disease (80,93). Tyrosine hydroxylase, the
rate-limiting enzyme in dopamine synthesis,
acts by production of a transient substrate–
radical–Fe2+/3+ complex and thus both uses
and produces ROS (94). Dopamine is
metabolized by monoamine oxidase, and
this process results in production of ROS
[see McGeer et al. (95)]. Dopamine can be
oxidized to form superoxide anion radical
and reactive quinones; the latter ultimately
form neuromelanin, a polymer of oxidized
dopamine, which accumulates in these neu-
rons and may cause cell damage (96,97).
The substantia nigra has much more iron
than other brain regions, and through the
Fenton reaction, Fe2+ can be oxidized to
Fe3+ and ROS (98). Iron binds to neurome-
lanin (99), where it may do double damage
(100). The excessive production of ROS
results in depletion of glutathione and other
antioxidants (101) and increased lipid
peroxidation (102).
As for many other diseases, the interac-
tions of the various metals and organics
implicated in neurodegenerative diseases
have been little studied. Unfortunately, we
have few adequate animal models of these
diseases, which makes determining how
these contaminants interact in these diseases
even more difﬁcult.
Cancer 
Cancer, in general, results from interactions
between environmental exposures and genet-
ics. Genetic factors alone may account for no
more than 5% of cancers (103). Thus, as for
the diseases discussed above, susceptibility is
critical to an understanding of cancer, and
many environmental agents act to alter sus-
ceptibility. Cigarette smoking is the single
most signiﬁcant factor and is responsible for
an estimated 30% of all cancer deaths and
85% of lung cancer deaths (104). Other fac-
tors include diet, pollutants, radiation, infec-
tious agents, and drugs. Despite the fact that
genetics alone does not account for most
cancers, cancer is essentially a genetic dis-
ease, in that environmental agents or viruses
can alter the genes regulating cell division.
But, the reality is that most of us are not
born with a genetic makeup that guarantees
that we will develop cancer. Some individu-
als are at increased risk of cancer because of
inherited genetic differences that influence
metabolic activation or detoxication of
carcinogenic substances, and propensity to
these inheritances may depend on ethnicity
or race. Age and gender also impart differ-
ences in susceptibility, whereas immune
suppression or inadequate nutrition may
also increase susceptibility (105).
The National Toxicology Program (106)
lists 65 substances that are known human
carcinogens, plus over 200 substances reason-
ably anticipated to be human carcinogens. A
number of these listings are actually of chem-
ical mixtures such as tobacco smoke and
alcoholic beverages. Others include metals
(arsenic, cadmium, hexavalent chromium,
and thorium as known carcinogens and
beryllium, lead, nickel, and selenium as prob-
able carcinogens), but the great majority are
organic molecules. Some of the same factors
implicated in neurodegenerative and cardio-
vascular diseases almost certainly play roles in
cancer, especially ROS production and cellu-
lar oxidative stress. Ames et al. (107) have
emphasized the role that antioxidants present
in fruits and vegetables play in preventing
cancer. ROS production, and/or reduction of
cellular systems to scavenge ROS, appears to
be a major factor in cell injury, cell death,
and aging at many sites.
Endogenous steroidal estrogens function
not only as hormones but also as carcinogens
[reviewed by Liehr (108,109)]. Estrogens
have been proposed to induce carcinogenesis
by multiple mechanisms including covalent
modification of the estrogen receptor
(110,111), induction of chromosomal
abnormalities (112,113), an epigenotoxic
mechanism (114), conversion of 17β-
estradiol to catechol estrogens and redox-
active and adduct-forming estrogen
quinones (108,115), and subsequent ROS-
mediated DNA damage (116,117).
Breast cancer exempliﬁes the difﬁculties
in understanding the interactions between
endocrine and carcinogenic actions. As with
all cancers, the etiology of breast cancer is
complex, with multiple risk factors. Lifetime
exposure to estrogens is a major risk factor
for breast cancer (118,119). Elevated serum
estrogen levels and increased urinary excre-
tion rates of estrone, estradiol, and estriol
have been detected in breast cancer patients
compared with controls (118). Post-
menopausal women living in countries with a
higher risk of breast cancer, such as the
United States or United Kingdom, have ele-
vated levels of urinary and/or serum estrogens
compared with women living in countries
with a lower risk of breast cancer, such as
Japan, China, and Singapore (120–123).
The hypothesis that persistent chlorinated
hydrocarbons play a role in the etiology of
breast cancer is highly controversial
(124–127). The ﬁrst study to suggest a corre-
lation between environmental estrogenic xeno-
biotics and breast cancer was by Falck et al.
(128). They measured the levels of various
chlorinated hydrocarbons in mammary adi-
pose tissue from women with malignant and
nonmalignant breast disease and found ele-
vated levels of several compounds including
PCBs, DDT, and DDE in tissue from women
with malignant disease. Others have found
(129–131) or not found (132–136) a relation-
ship between exposure and disease. A recent
meta-analysis of five previously published
reports concluded that there was no signiﬁcant
correlation between exposure to organo-
chlorines and breast cancer risk (137),
although this study could not rule out exis-
tence of genetically vulnerable subpopulations.
Feigelson et al. (138) proposed a multi-
genic model of breast cancer based on indi-
vidual susceptibility. They suggest that
genetic differences among women that result
in alterations of biosynthesis and metabolism
of endogenous estrogens explain differences
in breast cancer incidence. Feigelson et al.
(139) report that genetic polymorphisms in
two genes involved in estrogen metabolism,
CYP17 and HSD17B1, are related to breast
cancer incidence. Moysich et al. (140)
found that women with a high PCB body
burden and a variant CYP1A1 allele had a
higher incidence of breast cancer, whereas
there was no signiﬁcant association between
PCB concentration and breast cancer
among women who did not have the variant
allele (140). Millikan et al. (141) found a
statistically significant relationship between
risk of breast cancer and serum PCB levels
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white women, thus adding further support
to the possibility that, although the relation-
ship between PCB levels and breast cancer is
weak, it is signiﬁcant for vulnerable popula-
tions. Rundle et al. (142) reported similar
findings from investigating the relationship
between DNA damage in breast tissue due
to exposure to PAHs and a genetic deletion
in the gene encoding a xenobiotic detoxi-
fying enzyme, glutathione S-transferase M1.
Although the null glutathione S-transferase
M1 genotype did not predict breast cancer
cases, it did predict PAH–DNA adduct lev-
els in malignant versus benign breast tissue,
and PAH–DNA adducts are correlated with
breast cancer (143).
Diseases Involving Both
Physiologic Disruption 
and Cell Damage
Cardiovascular Disease
Cardiovascular disease is the major cause of
morbidity and mortality in developed coun-
tries such as the United States. Known risk
factors for cardiovascular disease, especially
ischemic heart disease, include genetic pre-
disposition, high-fat diets, smoking, and lack
of exercise. Cerebrovascular disease (“brain
attacks”) have etiology and risk factors simi-
lar to ischemic heart disease that lead to
myocardial infarctions.
Smoking is a major risk factor for
cardiovascular disease, and certainly smoking
is the ultimate example of exposure to a
chemical mixture. Cigarette smoking is
responsible for approximately 20% of the
500,000 deaths from cardiovascular disease
in the United States each year (104), and it
also contributes to cerebrovascular disease.
We have some evidence suggesting that
smoking has synergistic, not additive, effects,
with the other two major risk factors for
coronary heart disease (hypertension and
hypercholesterolemia) (144). The mecha-
nisms by which smoking results in athero-
sclerosis are only partially understood, but
the well-documented association is enough
to indicate that cardiovascular disease may
be secondary to exposure to environmental
toxicants. In addition, a relatively under-
appreciated body of evidence implicates cer-
tain metals and organochlorine compounds
as contributors to cardiovascular disease.
For metals, we have good evidence for
increased risk of ischemic heart disease from
arsenic exposure (145), and the elevated risk
(2.5-fold) remains after adjustment for sev-
eral other factors including hypertension and
diabetes. This effect also appears to be inde-
pendent of the peripheral artery disease seen
in arsenic poisoning. Mercury from ﬁsh has
been reported to lead to increased risk of
myocardial infarction, possibly through
promotion of lipid peroxidation (146).
Sørensen et al. (147) have reported that pre-
natal methyl mercury exposure results in
higher blood pressure at seven years of age.
Lead also has serious cardiovascular effects,
altering electrical activity and promoting
atherosclerotic changes and response to
transmitters (148). These actions are in addi-
tion to the evidence that chronic lead poi-
soning induces hypertension (149). The
mechanisms responsible for all these actions
of metals are unknown.
Studies of workers exposed to phenoxy
herbicides and dioxins have reported a sig-
nificant elevated overall morbidity and an
elevated risk of ischemic heart disease
(150,151). In the study of Flesch-Janys et al.
(150), the risk for morbidity from ischemic
heart disease increased in a dose-dependent
fashion with 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) and with all polychlori-
nated dioxin and furan exposures combined.
For the highest exposure category, the risk
ratio was 2.48 (95% confidence limits,
1.32–4.66). Michalek et al. (152) have
reported a significantly elevated increased
risk of death from circulatory system diseases
among enlisted ground troops exposed to
dioxin in Agent Orange in Vietnam. Vena
et al. (153) reported an increased risk for cir-
culatory diseases, especially ischemic heart
disease, in dioxin-exposed workers for an
International Agency for Research on
Cancer international cohort (relative risk,
1.67; 95% confidence limits, 1.23–2.26).
Cardiovascular disease has been found to be
elevated in the Seveso population exposed to
dioxin after a herbicide plant explosion
(154). Because coplanar PCBs are dioxinlike,
these observations are relevant to PCB expo-
sure as well. Some studies show that PCBs
contribute more to toxic equivalents for
dioxin than TCDD itself (155).
The mechanisms whereby dioxinlike
substances alter cardiovascular function are
uncertain, but the evidence suggests that
both physiologic changes and direct cell dam-
age are involved. Serum lipids are elevated in
PCB-exposed (156–159) and dioxin-exposed
(160) populations. Animal studies have
shown that sublethal exposure to TCDD is
associated with effects on lipid metabolism
(as reﬂected by increased serum cholesterol,
as well as generally increased serum triglyc-
eride concentrations) (161). Monkeys
exposed to dioxin and PCBs showed a 3- to
5-fold elevation in serum triglyceride concen-
trations (53) similar to what has been found
in numerous other animal studies [see Safe
(162)]. The abnormal lipid levels reflect
altered liver function. The liver increases in
size after exposure to TCDD in animals
(163) and humans (164), and the increased
serum lipids reflect induction of lipogenic
enzymes (165). Elevated serum lipids are a
well-documented risk factor for atherosclero-
sis and ischemic heart disease. Furthermore,
animal studies have shown that dioxin and
coplanar PCBs cause the production of ROS
(166,167), which in turn causes damage to
endothelial cells and promotes the formation
of foam cells and atherosclerotic plaques
(168–170). These actions are similar to those
caused by PAHs in tobacco smoke in human
endothelial cells (171). The combination of
elevations of serum lipids in the presence of
damage to endothelial cells is a clear formula
for cardiovascular disease.
Cerebrovascular disease has essentially
the same etiology as cardiovascular disease.
However, we are unaware of any studies in
the past that have investigated a relationship
between cerebrovascular disease and xenobi-
otic exposure, but we would expect the risk
factors to be similar to those for ischemic
heart disease.
Two important considerations relate to
cardiovascular disease. Despite the well-
known relationship to smoking, cardiovascu-
lar disease is not widely recognized as being
related to environmental factors; neverthe-
less, we have increasing evidence that a vari-
ety of environmental agents contribute to
this disease. Furthermore, in addition to the
direct damage that these toxins cause on
endothelial cells, alteration of normal liver
function, as reflected in abnormalities of
lipid metabolism, can serve as a factor that
signiﬁcantly increases risk of development of
cardiovascular and cerebrovascular diseases.
Cellular and Animal Models 
of Environmentally Induced
Disease
Steroidal Hormone Function 
and Chemical Mixtures
Steroid hormones are lipid molecules with
limited solubility in plasma and are accord-
ingly carried through the plasma compart-
ment to target cells by specific plasma
transport proteins. Each transport protein
has a speciﬁc ligand-binding domain for its
associated hormone. It is generally accepted
that the “free” form of the steroid hormone,
and not the conjugate of the hormone with
its plasma transport protein, enters target
cells and binds with the appropriate recep-
tor. Receptors for the steroid hormones are
proteins located primarily in the cell nucleus
or partitioned between the cytoplasm and
the nucleus. The unoccupied steroid recep-
tors may reside in the cell as heterodimeric
complexes with the 90-kDa heat-shock pro-
tein, which prevents the receptor from bind-
ing with the DNA until the receptor has ﬁrst
bound with its steroid hormone. Once the
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receptor complexed with the HR-HSP
undergoes a conformational change and is
considered to be activated. The activated
receptor binds with DNA at a specific site,
initiating gene transcription and eventually
resulting in a speciﬁc biologic response (e.g.,
cell proliferation and tissue restructuring).
The regulation of steroidal endocrine sys-
tems occurs through a series of feedback
mechanisms involving both hormone pro-
duction and receptor levels in target tissues.
Theoretically, environmental chemicals
that disrupt normal hormone function
could interfere at any of the steps described
above. However, most recent investigations
have focused on environmental chemicals
referred to as hormonally active agents, or
xeno-estrogens and xeno-antiestrogens,
which act through binding to the estrogen
receptor (ER). A chemical mixture may
contain a number of xeno-estrogens that
agonistically bind the ER, enhancing the
response of endogenous estrogens, or it may
contain a number of xeno-antiestrogens
that antagonistically bind the ER, inhibit-
ing the normal action of endogenous estro-
gens. Some estrogenic compounds in
chemical mixtures may exert an overall
estrogenic response not by binding to the
ER but rather by binding to estrogen
plasma transport proteins, resulting in more
“free” endogenous estrogen. A mixture con-
taining both xeno-estrogens and xeno-
antiestrogens may have no net biologic
response in the organism.
Many environmental chemicals have no
measurable estrogenic/antiestrogenic activ-
ity in simple in vitro systems yet produce
significant activity in vivo. This is the case
with numerous compounds that are acti-
vated by any one of the P450 cytochromes
(P450 or CYP). P450s are the stalwarts of
our detoxification system and, as such, are
involved in the metabolism of most xenobi-
otics as well as the metabolism of steroid
hormones. Xenobiotics and steroid hor-
mones also induce P450s. Environmental
mixtures may contain chemicals that
induce P450s, are metabolized by P450s, or
both. Induction of CYP1A1 and/or
CYP1B1 occurs when xenobiotics such as
TCDD or PAHs bind the AhR, and may
result in antiestrogenic activity through
increased metabolism and depletion of
endogenous estrogens (172). On the other
hand, compounds that are metabolized by
P450s may result in a net estrogenic effect
if they inhibit endogenous estrogens from
being metabolized. Figure 1 depicts some
of the ways in which an environmental tox-
icant may disrupt normal steroid function.
Clearly, predicting the activity of a chemi-
cal mixture containing a combination of
xenoestrogens/antiestrogens and P450
inducers and substrates on hormonal
function is a humbling task.
Research efforts in a number of labora-
tories [for reviews, see Liehr (173) and Parl
(174)] have led to the development of a con-
ceptual model of breast cancer that includes
the carcinogenic and hormonal activity of
endogenous estrogens, takes into considera-
tion genetically high-risk populations, and
can be expanded to include the role of chemi-
cal mixtures in the development of breast can-
cer. In the first step of this model, an
environmental chemical or estradiol is con-
verted in mammary tissue to a genotoxic
agent (an activated PAH or catechol
estrogen–derived quinone, respectively). In
the second step, the enzyme(s) involved in the
activation of the environmental chemical or
the metabolism of estradiol exists as a wild-
type and genetic variant differing in activity
level and results in a higher level of genotoxic-
ity in subpopulations. In the third step, estra-
diol increases proliferation of ER-positive
cells. Thus, in the presence of estradiol, if
both an ER-negative and an ER-positive cell
have randomly undergone a malignant trans-
formation, the ER-positive cell will be
selected, whereas the ER-negative cell will
grow less quickly, allowing time for DNA
repair or apoptosis. This model explains why
more than 60% of all breast tumors are ER
positive, whereas fewer than 20% of normal
breast epithelial cells are ER positive.
Although numerous chemicals induce
mammary tumors in laboratory animals, no
chemical carcinogen of the human breast has
been unequivocally identified. Although
individual pesticides, PCBs, and hydroxy-
lated PCBs are estrogenic in vitro and
in vivo, the estrogenic activity is apparent at
high (micromolar) concentrations only
(14,175–179). However, Sarkar et al. (180)
suggest that further investigation of
ethanol-associated damage to breast cell
DNA resulting from ROS is warranted.
Recently, data have been presented suggest-
ing that alcohol consumption may result in
increased bioactivation of the mutagen/car-
cinogen acetaldehyde and/or free radicals.
Castro et al. (181) demonstrated that incu-
bation of cytosol prepared from rat mam-
mary tissue with a xanthine oxidoreductase
cosubstrate (nicotinamide adenine dinu-
cleotide, hypoxanthine, xanthine, caffeine,
theobromine, or 1,7-dimethylxanthine) sig-
nificantly enhanced the biotransformation
of ethanol to acetaldehyde. These data sug-
gest that the in situ bioactivation of ethanol
to a carcinogen such as acetaldehyde and
potentially to free radicals may be involved
in alcohol-induced breast cancer. The con-
sumption of foods that provide cosubstrates
for xanthine oxidoreductase, such as caf-
feinated beverages and purine-rich meats,
may enhance the biotransformation of
ethanol to acetaldehyde.
PAHs, a group of environmental pollu-
tants, mutagens, and carcinogens, are bio-
activated primarily by P450s and epoxide
hydrolase. The resulting reactive PAH-
diolepoxides can bind DNA, forming PAH–
DNA adducts. Higher levels of PAH–DNA
adducts have been detected in the breast tis-
sue of cancer patients compared with that of
controls (143). In addition to binding DNA,
certain PAHs and/or their metabolites bind
the ER (182–186). It has been suggested
that by binding ERs, PAHs may accumulate
in the nucleus of cells, resulting in increased
rates of mutagenesis (183). Although this
hypothesis has not been adequately tested, it
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Figure 1. Toxicants as modulators of steroid hormone function.is supported by the finding that high doses
of estrogens or antiestrogens, given simulta-
neously or prior to a dose of the mutagenic
PAHs 3-methylcholanthrene or 7,12-
dimethylbenz[a]anthracene, inhibit the
development and/or growth of mammary
tumors (187–189). Presumably, the estro-
gens and antiestrogens occupy the ER, pre-
venting the binding of the PAH to ERs,
inhibiting mutagenesis. Humans are contin-
uously exposed to and have detectable levels
of PAHs, thus making these compounds
potentially important genotoxic agents in
the initiation of breast cancer.
Results from numerous studies indicate
that many chemicals in the environment,
including pesticides, PCBs, PAHs, phtha-
lates, phytoestrogens, and others, are estro-
genic in in vitro assays. However, the
potency of these compounds is very low
compared with endogenous estrogens
(10,000- to 200,000-fold lower), and it is
uncertain whether humans ever experience
an environmental mixture that results in a
net estrogenic effect. For example, individual
pesticides, PCBs, and hydroxylated PCBs are
estrogenic in vitro and in vivo in animals but
only when present at micromolar concentra-
tions (14,175–179). Rubin et al. (190)
reported that perinatal exposure to low doses
of bisphenol A in drinking water affects
body weight, estrus cycle patterns, and
plasma luteinizing hormone levels in adult
rats, and that lower doses had a greater effect
than higher doses. The concentrations used
were below those giving a uterotropic
response in ovariectomized females, indicat-
ing a unique susceptibility in the developing
organisms. However, in general these com-
pounds are in human blood and tissue at
nanomolar, not micromolar, concentrations.
Furthermore, it is not clear whether the
estrogenic activities of multiple individual
compounds are additive in human tissue.
Nevertheless, the fact that some of these
xenobiotics are persistent may result in
effects despite their low potency.
Two recent papers suggest that the total
activities of a mixture of individually weakly
estrogenic organochlorines are additive, and
that weakly estrogenic compounds can pro-
duce additive effects with low levels of
steroidal estrogens. Using two standard
pharmacologic methods for modeling the
interaction of chemicals in mixtures (con-
centration addition and independent action
models), Payne et al. (191) determined that
the combined effect of o,p´-DDT, p,p´-
DDE, β-hexachlorocyclohexane, and p,p´-
DDT on proliferation of MCF-7 cells was
additive even when the individual com-
pounds were present at levels below their
individual no-observed-effect concentra-
tions. Rajapakse et al. (192) used a yeast
reporter gene assay for bisphenol A and
o,p´-DDT to investigate the combined
action of weakly estrogenic chemicals with
estradiol. They found that “at approximately
equieffective concentrations corresponding
to molar mixture ratios between 1:20,000
and 1:100,000 (estradiol:BPA or o,p´-DDT)
substantial modulations of the effects of
estradiol became discernible.” These data
suggest that mixtures of weakly estrogenic
compounds are most likely to contribute to
an estrogenic effect in humans when the
estradiol levels are very low and the xenoe-
strogen concentrations are highest, a condi-
tion most likely to occur in children.
Rajapakse et al. conclude that the potential
health implications of additive combination
effects between xenoestrogens and steroidal
estrogens deserves serious consideration.
Whether a mixture of weakly estrogenic
chemicals results in estrogenic activity
depends not only on the concentration but
also on the combination of individual com-
pounds. Hany et al. (193) reported that a
mixture of PCBs prepared to reﬂect the PCB
congeners and concentrations routinely
detected in human breast milk was estrogenic.
Female rats whose mothers received the PCB
mixture had increased uterine weights at 21
days old. Other PCB mixtures tested at simi-
lar concentration were not estrogenic.
Du et al. (194) measured doubling times
in MCF-7 cell cultures treated with either
estradiol or one of two Chinese PCB mix-
tures, PCB3 and PCB5, which are similar in
congener composition to U.S. Aroclors 1242
and 1254, respectively. Relative proliferation
effects were calculated on the basis of
decreases in doubling time compared with
vehicle control and estradiol. PCB3 and
PCB5 were as potent as estradiol, producing
100% of estradiol’s proliferative effect at
concentrations of 0.03 and 0.6 nM. At
30 nM, treatment with PCB3 still resulted
in an 86% proliferative effect, whereas PCB5
showed no proliferative effect. Du et al. sug-
gest that PCB5 may have been toxic at
30 nM. These results are startling because all
previous reports have suggested that individ-
ual PCB congeners and mixtures are estro-
genic in the micromolar range and show no
effect at nanomolar and picomolar levels.
The reason for this discrepancy is unknown,
but it may be that PCB3 and PCB5 con-
tained a potent estrogenic contaminant
other than the PCB congeners.
Most of the mixtures to which humans
are exposed contain a variety of compounds
with estrogenic and antiestrogenic effects.
Results from a number of studies suggest
that metabolism of environmental chemicals
may produce more potent estrogens/anti-
estrogens (186,195). Also, most assays
measure the estrogenic activity of a
compound on basis of binding to ER and
activation of transcription. As mentioned
previously, a chemical agent can produce an
estrogenic response in vivo by other mecha-
nisms (e.g., alteration of ER levels, alteration
of endogenous estrogen metabolism).
Therefore, it is plausible that chemical mix-
tures may be more estrogenic/antiestrogenic
in vivo than predicted based on results from
in vitro assays. Another indication that mix-
tures of environmental compounds may be
antiestrogenic is the ﬁnding from a compre-
hensive chronic toxicity study of four com-
mercial PCB mixtures (Aroclors 1016, 1242,
1254, and 1260) in which rats received one
of the mixtures for 24 months. Females fed
the mixtures with the highest chlorine con-
tent (Aroclor 1260) had a significantly
decreased incidence of mammary neoplasms
compared with the control group (196).
Reduced Male Fertility
Perinatal exposure to chemical mixtures
alters sexual differentiation and may disrupt
normal hormone function if the chemicals
act as antiandrogens, estrogens, AhR aro-
matic hydrocarbon receptor agonists, or fetal
germ cell toxicants. Antiandrogens bind the
androgen receptor without activating it.
Antiandrogenic activity has been noted for a
number of different types of chemicals,
including pharmaceuticals (hydroxyflu-
tamide), pesticides (procymidone, vinclo-
zolin, o,p´-DDE), fungicides (vinclozolin),
and estrogens (diethylstilbestrol and estra-
diol). Perinatal exposure to antiandrogens
can be detected in laboratory animals as
decrease in anogenital distance, nipple reten-
tion, hypospadias, delay in preputial separa-
tion, decrease in sex accessory gland weights,
and inhibition of endogenous gene expres-
sion. Estrogens can produce antiandrogenic
effects either by inhibition of testicular
androgen secretion via blocking the secretion
of luteinizing hormone or by direct suppres-
sion of testosterone synthesis by Leydig cells.
Estrogens also alter male reproduction
through binding with the ER and activation
of specific gene responses. The antiandro-
genic effects of estrogens are detectable in
vivo in male laboratory animals as alterations
in mating behavior, serum levels of luteiniz-
ing hormone, and spermatogenesis. AhR
agonists (TCDD, non-ortho-substituted
PCBs) bind the AhR and induce P450s that
can activate procarcinogens and alter the
metabolism of steroid hormones.
The environmental toxicant whose
adverse effects on male reproduction have
been the most studied is TCDD. In a study
by Moore et al. (197), adult male rats given
single doses of TCDD exhibited decreases in
plasma testosterone and dihydrotestosterone
concentrations by 90 and 75%, respectively,
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prostate weights. Moore et al. concluded
that whereas the TCDD-induced depression
in plasma testosterone concentration
appeared to be the primary event observed,
the mechanism by which testosterone
concentrations decreased remains unknown.
A series of studies conducted to examine
the effects of in utero and lactational expo-
sure to TCDD on adult male rats showed a
decrease in androgenic status (lowered
testosterone levels), altered sexual behavior,
decreased serum luteinizing hormone levels,
and decrements in spermatogenesis and
reproductive capability (198–200). Another
series of studies reported different effects for
in utero versus lactational exposure (201), a
decrease in the responsiveness of ventral
prostate after in utero and lactational expo-
sure (202), and partial demasculinization
and feminization of male sex behavior with
in utero and lactational exposure (203). Gray
et al. (204) showed that prenatal exposure to
TCDD permanently reduced sperm number
and sex accessory weights but did not alter
testosterone levels. Furthermore, a single
exposure to TCDD on gestational day 15
was sufﬁcient to permanently reduce epididy-
mal sperm reserves (205). It has often been
stated that the effects of TCDD are at least
partially due to catabolism of testosterone
because TCDD is a potent inducer of
P450s. Although it is clear that TCDD can
increase the catabolism of testosterone in
vitro, a study that measured TCDD-induced
catabolism in vivo found no evidence that
TCDD altered the disappearance rate of
testosterone (206). At this time how TCDD
produces its multiple effects on male repro-
duction is still not clear.
Reproductive effects of lead exposure
have been well documented in laboratory
animals. In general, results from the experi-
mental studies are consistent with the epi-
demiologic studies. Exposure to lead acetate
in drinking water results in a decrease in
sperm count (207–209), a decrease in basal
and chorionic gonadotropin-stimulated
testosterone production (210), and a
decrease in serum testosterone as well as
early onset of capacitation (211).
Numerous mechanisms of action have
been demonstrated or suggested to account
for the observed effects of PCBs and inor-
ganic lead on the male reproductive system.
It is clear that perinatal exposure to either
Aroclor 1242 or 1254 results in hypo-
thyroidism (212). Because thyroid hor-
mones directly suppress mitogenesis of
neonatal Sertoli cells, the hypothyroidism
may induce increased neonatal Sertoli cell
proliferation, and a larger Sertoli cell popu-
lation may be responsible for the increases
in germ cell numbers, testis weight, and
daily sperm production that characterize
this phenomenon. Support for this hypothe-
sis comes from the results of a Sertoli cell
proliferation assay in PCB-treated animals
(212). Fifteen-day-old rats (control and
PCB treated) received tritiated thymidine
via injection 2 hr before death, and their
testes were fixed in 10% formalin. Analysis
of incorporation of [3H]thymidine revealed
greater proliferation in Sertoli cells in testes
from PCB-treated animals than in testes
from controls. Although the increase in
testis weight induced by PCBs was less than
that induced by the goitrogen 6-propyl-2-
thiouracil, both PCBs and 6-propyl-2-
thiouracil effectively reduced the thyroid
hormone thyroxine (T4). Thus, it appears
that factors other than the reduction of T4
are affecting the testes weights of PCB-
treated male rats.
PCBs bind the AhR and induce P450s
that may catalyze the catabolism of steroid
hormones or decrease the production of
testosterone. Machala et al. (213) studied the
effects of chronic exposure to PCBs on
cytochrome P450 systems and steroidogene-
sis in liver and testes of the bull and observed
inductions of hepatic ethoxyresorufin
O-deethylation and 6β-hydroxylation of
testosterone. They also found a high level of
PCB-inducible androstenedione formation.
PCB exposure reduced testicular microsomal
P450s and affected androstenedione forma-
tion and 16β-hydroxylation of testosterone.
Mitochondrial CYP11A, the rate-limiting
enzyme of steroidogenesis, was inhibited by
50% in the testes of exposed animals.
Machala et al. suggest that this activity, as
well as the hepatic testosterone 6β-hydroxy-
lation and hepatic and testicular androstene-
dione formation, may significantly
contribute to the decrease in testosterone
levels often observed with PCB exposure. In
the above-described study and others, it
appears that perinatal exposure to PCBs can
result in “enzymatic imprinting.” In another
study, a single perinatal exposure to Aroclor
1254 permanently altered the adult expres-
sion of hepatic and testicular P450s (214).
Oxidative Stress and DNA Damage
in Sperm
Phospholipids are the major component
(60–70%) of the lipids in sperm cells (215),
and the phospholipids have a high content of
polyunsaturated fatty acids. Consequently,
sperm cells are susceptible to lipid peroxida-
tion from various ROS such as superoxide
anions, hydroxyl radicals, and hydrogen per-
oxide. Jones et al. (216) found that more
than 60% of the major polyunsaturated
phospholipid fatty acid in human spermato-
zoa, docosahexaenoic acid, was lost after
exposure of the spermatozoa for 2 hr to the
prooxidant catalyst system of iron/ascorbate.
The fatty acid degradation was accompanied
by an increase in the lipid oxidation byprod-
uct malondialdehyde (MDA). This degrada-
tion of phospholipids can lead to destruction
of cell membranes. Furthermore, the ROS
can react with DNA molecules, leading ulti-
mately to mutations affecting both spermato-
genesis and the genetic status of progeny.
Investigations into the causes of infertility in
human male populations have shown that
MDA levels and/or levels of a biomarker for
oxidative DNA damage, 8-hydroxy-2´-
deoxyguanosine (8-OHdG), were statistically
associated with decreases in indices of sperm
quality such as sperm number and sperm
motility (217,218). Oxidation of spermato-
zoa in vitro also demonstrated that 8-OHdG
levels were negatively correlated with sperm
motility. However, one study showed that
the MDA levels in seminal plasma from
males who were infertile and had poor
indices for sperm quality were similar to
MDA levels in seminal plasma from fertile
males with good indices of sperm quality
(219). These results can be explained by the
data obtained by Jones et al. (216), who
found that lipid peroxidation took place
within the sperm cells, whereas the seminal
plasma had antioxidant properties.
When infertile men received the anti-
oxidants vitamin E and/or vitamin C, their
in vitro fertilization rates increased and
sperm MDA levels decreased (220), and
sperm concentration increased and sperm
8-OHdG decreased (217). Depletion of
dietary vitamin C had the effect of increas-
ing sperm 8-OHdG levels (221). Cigarette
smoking is a life-style factor that has adverse
effects on sperm, and it also leads to
increases in sperm 8-OHdG (222,223).
Alcohol consumption has been associated
with sperm damage, and we have evidence
that alcohol consumption leads to increased
oxidative stress in many tissues, including
the formation of 8-OHdG in hepatic mito-
chondrial DNA of rats (224). However, an
association between alcohol consumption
and oxidative damage in sperm has not been
reported in the literature.
Exposure to lead increases generation of
ROS. Using an assay based on the chemi-
luminescent signal produced from the reac-
tion of luminol with ROS, Hsu et al. (225)
found that sperm from lead-exposed rats had
increased ROS levels that were inversely cor-
related with sperm count, motility, and
oocyte penetration rate. The mechanism of
the formation of ROS by lead has not been
resolved. Marchlewicz et al. (226) demon-
strated that many spermatozoa of lead-
exposed rats had abnormal reactions of
antioxidant enzymes in the midpiece,
suggesting that impairment of free-radical
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factor in lead-induced ROS formation.
Although no studies report oxidative stress in
sperm following exposure to PCBs, the
ortho- and para-hydroxylated metabolite of
PCBs can be converted to quinones by per-
oxidases (227). The quinones can undergo
redox cycling to produce ROS, and 8-
OHdG is formed in an in vitro system of calf
thymus DNA, lactoperoxidase, and 3,4-
dichloro-2´,5´-dichlorobiphenyl (228).
Therefore, a high potential exists for oxida-
tive reactions to occur in sperm cells exposed
to PCBs and other organochlorines because
compounds in these cells are readily oxidized
by a variety of chemicals as described above.
Molecular Mechanisms 
of Toxicant Interactions
Deciphering and predicting the complex
interactions among organic, inorganic, and
organometallic toxicants at the cellular and
molecular levels present enormous challenges
to toxicologists. A number of recent
advances in the characterization of responses
to xenochemicals at the molecular level have
advanced our understanding of potential
interactions among toxicants. Receptors may
act as chemical sensors that mediate
responses to stimuli by activating stress–
response systems, inducing detoxification
enzymes, and mounting cellular responses to
hypoxia and oxidative stress. Additional sig-
nals may be initiated or blocked by the bind-
ing of toxicants or metabolites to hormone
receptors and transporters. In the past several
years research has further elucidated molecu-
lar pathways of signal transduction and
cross-talk among the various stress–response
pathways. Moreover, recent identiﬁcation of
the potential roles of proteins previously
referred to as “orphan receptors” in mediat-
ing responses to mixtures of xenochemicals
has greatly advanced our understanding of
the molecular events subsequent to toxicant
exposure. Ongoing identification and char-
acterization of the human homologs of
receptors and signaling pathways that have
been described in experimental animals will
help us to determine the human responses to
xenochemicals and mixtures thereof and to
identify and explain differences in suscepti-
bility between humans and other species.
Chemical Mixtures Activate Multiple
Receptors
Activation of gene transcription by mixtures
of xenochemicals may involve multiple
receptors and signaling pathways. The role
of multiple receptors in endocrine disruption
has long been hypothesized to be the result
of the induction of various phase I and
phase II enzymes that catalyze the metabo-
lism of xenobiotics and endogenous
hormones (229). The inductive responses to
xenobiotics have long been referred to as the
3-methylcholanthrene (3-MC) type, pheno-
barbital (PB) type, or mixed (230) because
various compounds and mixtures elicit pat-
terns of gene expression similar to the PAH
3-MC, the barbiturate PB, or a mixture of
the two. The hallmark of the PB-type
response is the induction of P450s of the
CYP2B subfamily, whereas the 3-MC–type
response is indicated by induction of P450s
of the CYP1A subfamily. In addition to 3-
MC and PB, the steroid derivative pregne-
nalone 16α-carbonitrile (PCN) is a known
inducer of gene expression, notably of the
genes encoding P450s of the CYP3A and
CYP2B subfamilies; a number of xenochem-
icals also appear to mimic PCN in inducing
gene transcription. Probably the best exam-
ple of the activation of multiple receptor
pathways after exposure to a chemical mix-
ture is that elicited by Aroclor formulations
of PCBs because they comprise complex
mixtures of various di-ortho-, mono-ortho-,
and non-ortho-substituted congeners with
differing degrees of chlorine substitution.
Aroclors elicit 3-MC–, PB-, and PCN-type
responses in rodents (231,232), and PCB-
exposed humans appear to show a similar
mixed pattern of enzyme induction (233).
It is well established that the 3-MC type
of enzyme induction proﬁle elicited by chlori-
nated dioxins and dibenzofurans, PAHs, and
non-ortho-substituted PCBs is mediated by
the AhR. Both the AhR and its heterodimer-
ization partners, the AhR nuclear translocator
(ARNT) and ARNT2 (234,235), are mem-
bers of the Per-ARNT-SIM (PAS) family of
basic helix-loop-helix transcription factors,
which also includes hypoxia-inducible factor
1α (HIF-1α). In contrast, current efforts have
shown that the PB- and PCN-type responses
are mediated by members of the nuclear
receptor family of transcription factors that
includes the steroid and thyroid hormone
receptors. Recent studies have provided con-
vincing evidence that two orphan receptors of
the nuclear receptor family, the constitutive
androstane receptor (CAR; also referred to as
the constitutively active receptor) and the
pregnane X receptor (PXR), mediate the PB-
and PCN-type responses (236–238).
CAR and PXR as Mediators of the
Mixed PB- and PCN-Type Responses
Changes in gene expression in response to
exposure to a variety of nonplanar xeno-
chemicals, including ortho-substituted
PCBs and various pesticides, were similar to
those elicited by PB and PCN. Because
mixtures may contain multiple agonists/
antagonists of several receptors and because
the genes that are induced by PB and the
genes induced by PCN overlap (e.g., both
chemicals induce P450s of the CYP2B and
CYP3A subfamilies), the factors controlling
gene transcription have been unknown
until quite recently. Identification of the
PB-responsive elements in the 5´ regions of
the CYP2B genes (239) and subsequent
identiﬁcation of CAR as the receptor that is
activated by PB exposure were major
advances (240–242). Similarly, genetic ele-
ments responsible for the binding of PXR
have been identified (238). Both PXR and
CAR form heterodimers with the retinoid
X receptor (RXR) to activate gene transcrip-
tion, and recent studies indicate that the
two receptors can bind the same DNA ele-
ments (243), which explains the ability of
PB to cause some induction of CYP3A and
PCN to induce CYP2B. Although the
effects of various xenochemicals on PXR
and CAR are under investigation, we now
know that that ortho-substituted PCBs acti-
vate the mouse PXR (244) and human CAR
(240). The identification and characteriza-
tion of RXR, PXR, and CAR from rodents
and humans, and studies of their interac-
tions with the regulatory elements of a
number of genes have indicated that ligand
afﬁnity and speciﬁcity cannot be assumed to
hold in across-species comparisons (245);
agonist/antagonist interactions with the
human receptors must be evaluated. The
recently developed cellular and molecular
techniques and assay systems using reporter
genes will allow us to determine binding
afﬁnity and efﬁcacy of agonists and antago-
nists of these receptors in vitro. The genes
encoding xenobiotic-metabolizing enzymes,
P450s, and glucuronosyltransferases are the
most thoroughly characterized regarding
induction by PB and PCN, implicating the
involvement of CAR and PXR. It is
thought that the expression of a significant
number of other genes is regulated by the
action of CAR and PXR (246) and that
regulation by CAR and PXR is not limited
to the liver but is observed in extrahepatic
tissues including brain (247).
Mixtures and AhR-Mediated Effects
Many environmental mixtures contain
numerous AhR agonists, principally PAHs,
PCDDs, polychlorinated dibenzofurans, and
PCBs. Exposure to AhR agonists may occur
as a result of various combustion sources,
including open burning (248) and environ-
mental tobacco smoke. Although individual
compounds and mixtures will elicit varied
responses because of agonist/antagonist
properties and persistence of the response
dependent on rate of metabolism of the lig-
ands, the mechanism of AhR-mediated gene
transcription elicited by an agonist is cur-
rently well defined. Upon ligand binding
and release of 90-kDa HSP, ARNT is bound
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nucleus, where its binding to xenobiotic-
responsive elements found in gene 5´-regula-
tory regions leads to induction of genes
encoding several phase I and phase II
enzymes referred to as the aromatic hydro-
carbon (Ah) gene battery. Enzymes of the
Ah gene battery whose expression is directly
regulated by the AhR include the P450s,
CYP1A1, and CYP1B1, UDP-glucuronosyl-
transferase 1A6, glutathione S-transferase Ya,
NAD(P)H:quinone reductase 1 (NQO1),
and class 3 aldehyde dehydrogenase. The
molecular events leading to transcriptional
activation of the archetypal AhR-regulated
gene CYP1A1 have been characterized in
considerable detail (249,250). Recent studies
have focused on the detailed functions of
speciﬁc domains of the AhR (251), functions
of the AhR within the chromatin setting
(252), interactions of the AhR with other
proteins that either enhance (253–257) or
inhibit (258) its function, and regulation of
the AhR response by proteosome-mediated
degradation of the AhR (259,260). The
recent identiﬁcation and characterization of
the gene encoding the AhR repressor (261)
represent yet another level of regulation in the
complex control of AhR-mediated responses.
Recent results support the longstanding
hypothesis that the AhR is a receptor for some
unidentified endogenous hormone or
autocrine factor (262–264) and continue to
spur efforts to identify endogenous AhR lig-
ands. Although a number of endogenous
compounds have been shown to activate the
AhR, the most likely candidate activators
appear to be derivatives of indole (265).
Of the diseases involving the AhR and
AhR-regulated genes, PAH-induced lung
cancer may be one for which we have a sig-
niﬁcant degree of understanding of the role
of toxicants at the molecular level (266). The
metabolic activation of PAHs to the ultimate
carcinogens, the diol epoxides, was elegantly
described over 20 years ago (267,268). The
enzymes primarily responsible for the meta-
bolic activation of PAHs including
benzo[a]pyrene are CYP1A1, CYP1B1, and,
to a lesser extent, CYP1A2 in concert with
epoxide hydrolase (269). Both CYP1A1 and
CYP1B1 are expressed in human lung (270).
CYP1B1 appears to be more active than
CYP1A1 in the conversion of a number of
PAHs to genotoxic intermediates (269). In
the presence of epoxide hydrolase, both
CYP1A1 and CYP1B1 catalyze the conver-
sion of the archetypal PAH, benzo[a]pyrene,
to its 7,8-dihydrodiol, and both enzymes can
in turn metabolically activate this
benzo[a]pyrene metabolite to a mutagenic
form (269,271,272). Covalent adducts,
formed by the reaction of PAH diol epoxide
metabolites with guanine in mutational
hotspots of critical genes such as that of the
p53 tumor suppressor (273,274), may initi-
ate tumorigenesis if not efﬁciently repaired.
PAHs are invariably found as mixtures in the
environment (e.g., products of partial com-
bustion, coal tars, environmental cigarette
smoke), and the interactions among PAHs
may be quite complex. The toxicity and car-
cinogenicity of a PAH mixture may depend
on the net activities of CYP inducers (AhR
agonists or antagonists), the prevalence of
enzyme inhibitors versus substrates for bioacti-
vation, and the activation or inhibition of
metabolic pathways leading to nontoxic/non-
carcinogenic metabolites (275–279). Results
of recent studies indicate that the formation of
diol epoxides may not be the only metabolic
pathway involved in PAH-induced carcino-
genesis. Burczynski and Penning (280) have
recently shown the propensity of various
PAH metabolites to be oxidized to carcino-
genic quinones catalyzed by aldo-keto reduc-
tases. Some of the PAH-derived quinones are
also AhR agonists. The pivotal role of NQO1
in preventing cellular damage and mutations
caused by PAH-derived quinones (281) was
shown in studies with the NQO1 gene
knockout mouse, which is more susceptible to
PAH-induced carcinogenesis (282,283).
Although we understand the roles of
AhR-regulated enzymes in PAH-induced
cancers reasonably well, a number of toxic
effects of AhR ligands, including the hall-
marks of TCDD toxicity, the wasting syn-
drome and immune suppression, have been
difﬁcult to explain in terms of the induction
of the Ah battery of xenobiotic-metabolizing
enzymes. Recent studies have shown that the
AhR-mediated responses are not limited to
effects involving these enzymes; rather, AhR
ligands affect development (284), regulation
of the cell cycle (262), and apoptosis and
may do so through a subset of molecular
interactions that are only currently being
defined. The teratogenic effects of TCDD
have long been known, and a role of the AhR
in development has been suspected. Targeted
inactivation of the AhR gene has indicated
physiologic roles of the AhR in normal devel-
opment in the absence of exogenous AhR lig-
ands because AhR gene knockout mice
showed developmental abnormalities includ-
ing liver defects and delayed population of
peripheral organs of the immune system
(284). Interestingly, inactivation of either of
the genes of the dimerization partners of the
AhR, ARNT or ARNT2, is far more devas-
tating than inactivation of the AhR gene
because both ARNT and ARNT2 gene dis-
ruptions are embryonically lethal (235,285).
This has been attributed largely to the fact
that ARNT and ARNT2 are also hybridiza-
tion partners of HIF-1α (ARNT is also
referred to as HIF-1β) and possibly other
PAS proteins; lethal defects in angiogenesis
and placental development of ARNT have
been attributed to disruption of HIF-1α sig-
nal transduction. Studies employing condi-
tional disruption of the ARNT gene have
confirmed that both AhR-mediated and
HIF-1α–mediated gene transcription are lost
when the ARNT gene is inactivated (286).
Recent studies suggest cross-talk between
the AhR-mediated and HIF-1α–mediated
pathways, which may explain additional
effects of TCDD and other AhR agonists
(287–289). If competition for ARNT exists
between AhR and HIF-1α, TCDD and
other persistent AhR agonists may, through
sequestration of ARNT, compromise HIF-
1α–mediated gene transcription. HIF-1α
regulates expression of vascular endothelial
growth factor, glucose transporters, and gly-
colytic enzymes. Because deﬁcits in both glu-
cose transport (290) and the activities of
several glycolytic enzymes have been impli-
cated in the wasting syndrome of acute
TCDD toxicity, this proposed mechanism of
AhR/HIF-1α cross-talk has received consid-
erable attention. This cross-talk has been sug-
gested to explain some of the effects of
TCDD, such as those on vascularization that
have been observed in some animal models,
that have not been described mechanistically.
It would seem to follow from this mecha-
nism that induction of enzymes and xenobi-
otic or endobiotic metabolism would not be
involved in some of the more profound
effects of AhR ligands because the ability of
compounds and mixtures to cause persistent
activation of the AhR would appear to be the
critical factor in the sequestration of ARNT.
AhR agonists have also been shown to
exert effects is on cell proliferation. Studies
from several laboratories indicate that AhR is
involved in the regulation of progression
through the cell cycle (262,291–293) and
that the AhR may also influence whether
cells undergo apoptosis (294). The AhR, but
not ARNT, was recently shown to interact
directly with the retinoblastoma protein
(RB), delaying cell cycle progression
(291,292). Activation of the AhR was also
recently shown to induce expression of
P27Kip27, a cyclin/cyclin-dependent kinase
inhibitor, which was also associated with a
delay in cell cycle progression through G1
(293). These AhR-mediated effects on the
cell cycle would appear to be entirely inde-
pendent of the Ah battery of xenobiotic-
metabolizing enzymes. It is hypothesized
that a delay in cell-cycle progression would
permit the cell time to repair oxidative or
adductive damage that may have occurred as
a result of elevated rates of P450-catalyzed
metabolism. Recent studies have also indi-
cated a role of the AhR in regulating apopto-
sis of human oocytes. The Bax gene, which
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be Ah responsive, and it induced PAH but
not by TCDD in oocytes (294). This AhR
ligand speciﬁcity raises interesting questions
as to the mechanism involved. It is possible
that the effect requires metabolism of the lig-
and, possibly to a reactive intermediate. If
this is the case, the effect would likely not be
seen with some mixtures of AhR agonists.
Heavy Metal–Organic Toxicant
Interactions 
Heavy metals are often co-contaminants
with organic toxicants in the environment.
Thus, a number of studies have been initi-
ated to investigate their toxic interactions at
the molecular level (295). A signiﬁcant com-
ponent of the toxicity of a number of heavy
metals, including cadmium, chromium, and
arsenic, results from the fact that they are
pro-oxidant; that is, they lead to generation
of ROS and oxidative stress (296). The com-
bination of metal-induced oxidative stress
with other mechanisms of toxicity induced
by organic toxicants is of signiﬁcant concern.
In addition, a number of organic toxicants
including TCDD, PCBs, and PAHs may
also induce oxidative stress (167,297–299).
The effects of co-exposure to metals and
organic toxicants may therefore be com-
pounding. However, there appear to be
some physiologic mechanisms by which the
effects of pro-oxidant metals and organic
toxicants are mutually abrogated at the mol-
ecular level. Our understanding of the
metal–organic toxicant interactions has
advanced signiﬁcantly because of the recent
elucidation of several intracellular stress–
response signaling pathways and the points
of cross-talk among them.
Pro-oxidant metals, and indeed, other
toxicants that elicit oxidative stress, induce
expression of a battery of genes whose func-
tions appear to be to limit oxidation, protect
cells from free-radical damage, and prevent
neoplasia. These include, among others,
heme oxygenase 1 (HO-1), the ferritin
L-gene, expression of NQO1, γ-glutamyl-
transferases, and γ-glutamylsynthetase.
Regulation of these genes occurs through
antioxidant response elements (also referred
to as electrophilic response elements) in the
promoter regions of the genes (300); these
are sites of interaction of the nuclear factor
(Nrf) group of transcription factors
(301–303). The HO-1 gene is well character-
ized with respect to induction by stresses and
metals, including arsenic III, zinc, and cad-
mium (304). The role of HO-1 induction as
a defense against oxidative stress is not hard
to envision because heme is pro-oxidant,
whereas bilirubin, the ultimate product of
heme degradation, is an antioxidant. P450-
catalyzed metabolism is recognized as a
source of free radicals, notably when futile
catalytic cycles occur with poorly metabo-
lized substrates such as PCBs and TCDD
(305,306). Coincident with the induction
of HO-1 by arsenite is the reduction of the
expression of P450s of several gene families
(307,308). Although heme availability for
the prosthetic group of P450 is undoubt-
edly at least partially responsible for the
effect, there appear to be several pathways
in which oxidant signals result in an effect
on P450 expression.
We have considerable evidence of cross-
talk involving stress signals and AhR-
mediated gene transcription that may
determine physiologic responses to environ-
mental mixtures. We have known for some
time that oxidative stress causes a down-
regulation of the AhR-regulated P450s
CYP1A1 and CYP1A2 (309,310). Recently,
pro-oxidant metals cadmium, chromium,
and arsenic disrupted AhR-mediated induc-
tion of the CYP1A1 and NQO1 mRNAs in
Hepa-1 cells (295). A potential mechanism
of the effect involves the stress–response
transcription factor nuclear factor-κB (NF-
κB), which is activated by a number of stim-
uli, including oxidants (311,312). Low levels
of arsenite activate NF-κB (313,314); how-
ever, higher levels inactivate NF-κB by bind-
ing to a critical cysteine (315). NF-κB
activation leads to induction of a number of
genes mediating inflammatory responses in
immune cells, but NF-κB appears to have
functions in other cell types and may control
whether a cell undergoes, or is rescued from,
apoptosis. A direct binding interaction of the
AhR and the NF-κB subunit, RelA, has been
demonstrated, and the interaction was shown
to suppress AhR-mediated gene transcription
(258). This role of NF-κB may explain the
negative effect of oxidative stress on CYP1A1
inducibility, although we also have evidence
for a role of NF-1 in this effect (310). The
AhR–RelA interaction may also explain the
effect of certain cytokines in reducing
CYP1A inducibility (316,317). The AhR–
RelA interaction may represent a mechanism
by which oxidative stress resulting from P450
catalytic activity is minimized, similar to the
induction of HO-1.
Summary
Toxicant Interactions
The discussion above obviously addresses
only a small subset of the possible interac-
tions of toxicants at the molecular level.
Figure 2 depicts some of the signaling path-
ways that may be affected by chemical mix-
tures, and the ways in which they may
interact, based on the current literature.
Even when we consider a limited number of
signaling pathways, the potential not only
for additivity and synergism but also for
antagonism of toxicity is clear (318). It is
apparent that stress–response pathways inter-
act to enhance cellular defense mechanisms
and limit metabolism that potentially leads
to cellular damage.
Individual Susceptibility to Toxicant
Mixtures
Susceptibility of an individual to the toxic
and carcinogenic effects of a chemical mix-
ture is believed to be affected to a signiﬁcant
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Figure 2. Signaling pathways and toxicant interactions. Glut-1, glucose transporter 1; Nrf2, nuclear factor-
drythrod 2-related factor 2; RB, retinoblastoma protein; VEGF, vascular endothelial growth factor.degree by genetics. Identiﬁcation of alleles of
specific genes associated with increased risk
of diseases such as cancer is an ongoing
process (266,319,320). However, suscepti-
bility to an environmentally induced disease
may involve not a single gene but rather a
series of genes, some having a major effect
on susceptibility, others having a modifying
effect (321). For example, cancer susceptibil-
ity associated with a gene affecting the rate
of metabolic activation of a procarcinogen
could be highly inﬂuenced by the nature of
genes encoding phase II detoxifying enzymes
for reactive metabolites and DNA repair
enzymes responsible for removing adducts
(9,322). The advent of new gene array tech-
nology will not only allow the analysis of
global patterns of gene expression in
response to xenobiotic/mixture exposure
(323–325) but also could eventually allow
the genomewide identification of polymor-
phisms and mutations that may be used to
predict an individual’s response to drugs
(326) or other xenobiotics. These new
approaches of pharmacogenomics and toxi-
cogenomics will undoubtedly be of para-
mount importance in unraveling the
complex interactions among environmental
toxicants and in determining their effects on
human health. 
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